Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Suzhou Connect Biopharmaceuticals through its subsidiary Connect Biopharmaceuticals has entered into an agreement to license Arena Pharmaceuticals' two series of anti-inflammatory compounds as well as a new method for treating diseases.
Subscribe to our email newsletter
Under the agreement, Suzhou will use anti-inflammatory compounds and the method to develop small molecule compounds to treat allergic rhinitis and atopic dermatitis.
Financial terms and molecular targets of Suzhou’s deal with Arena have not been disclosed.
Connect Biopharmaceuticals co-founder and CEO and Arena immunology former director Zheng Wei said the agreement provides the company with an opportunity to address such limitations by advancing drug candidates with novel mechanisms of action.
"It comes on the heels of our recent financing round, which enables us to fund the program into clinical proof-of-concept studies," Wei added.
Arena Pharmaceuticals executive vice president and chief scientific officer Dominic Behan said, "We look forward to Connect’s advancement of the novel anti-inflammatory compounds that comprise this program."